MENLO PARK, Calif.--(BUSINESS WIRE)--Charisela Technologies, Inc., a manufacturer of advanced flow cytometry assays, announced today that it has begun shipments of its next generation Human and Mouse IgG kappa and IgG lambda assays, the first products in its HyFlo-Ig product line of research use only (RUO) assays. These assays can be used in a variety of situations with hybridomas such as monoclonal antibody (mAb) therapeutics production and basic research.